BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong

February 10th, 2014 BiondVax, developer of a universal flu vaccine, announced receiving approval from Hong Kong’s patent office to register its patent concerning Multimeric Multiepitopes for the Company’s universal flu vaccine, as well as an approval from the US patent office for the completion of the testing process for patent registration. As part of the US registration process, the patent was found eligible and currently …